Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 10/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718369 | 0.82 | POLB (0.41) | MEN1KMT2ASYKZAP70 | |
| SCHEMBL2718598 | 0.81 | MEN1 (0.38) | MEN1KMT2ASYKZAP70 | |
| SCHEMBL2716274 | 0.76 | RXFP1 (0.45) | MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL10272085 | 0.74 | LMNA (0.43) | MEN1KMT2ASYKLMNA | |
| SCHEMBL2718549 | 0.70 | HSD17B10 (0.39) | PDE4BKMT2APPARGCYP1A2 | |
| SCHEMBL1949965 | 0.68 | LMNA (0.49) | PPARGSYKLMNAZAP70 | |
| SCHEMBL2717224 | 0.67 | SYK (0.43) | PPARGSYKZAP70 | |
| SCHEMBL17069448 | 0.67 | LMNA (0.48) | PPARGSYKLMNAZAP70 | |
| SCHEMBL282929 | 0.66 | POLB (0.39) | MEN1KMT2APPARGSYKZAP70 | |
| SCHEMBL17069444 | 0.66 | LMNA (0.47) | PPARGSYKLMNAZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317029-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012061415-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061415-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317029-A1 | OXYPYRIMIDINES AS SYK MODULATORS | SYK, BTK, FYN | PDE4B 2128/4885MEN1 4788/4885KMT2A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.